Evaluation of the Safety and Tolerability of Lu AH69593 in Healthy Adults and Adults with Narcolepsy

The primary objective of this study is to evaluate the **safety** and **tolerability** of Lu AH69593 in adults who are either healthy or diagnosed with **narcolepsy**. This is clinically relevant as it aims to determine the potential adverse effects and overall acceptability of the treatment, which is crucial for ensuring patient safety and guiding future therapeutic use. No secondary objectives are provided for this study.

The clinical trial focuses on participants diagnosed with **narcolepsy**. The study population includes both male and female subjects, with an age range categorized as adults. The sponsor has not provided the total number of participants involved in the trial. The selection process for the trial population is not detailed, and there is no information regarding specific lifestyle considerations such as diet, physical activity, or habits. The trial does not involve a vulnerable population, and no key inclusion or exclusion criteria have been specified by the sponsor.

The clinical trial is designed to evaluate the **safety** and tolerability of Lu AH69593 in adults who are either healthy or diagnosed with **narcolepsy**. This study is structured as a Phase 3, randomized, double-blind, controlled trial. The estimated recruitment start date is June 1, 2025, with an anticipated end date of November 30, 2026. Participants will be involved in the study for a duration that aligns with the trial's timeline, subject to their continued eligibility and adherence to the study protocol.

The sequence of study visits begins with an inclusion (screening) visit, where potential participants are assessed for eligibility based on predefined criteria. Following successful screening, participants will be randomized and commence the treatment phase. Throughout the trial, there will be scheduled follow-up visits to monitor the participants' health, assess the drug's safety profile, and collect data on its tolerability. These visits are critical for ensuring participant safety and the integrity of the trial data. The study will conclude with an end-of-study visit, where final assessments are conducted, and participants are debriefed.

Participant involvement is expected to last until the trial's completion, unless early termination is warranted. Conditions that may lead to early withdrawal include adverse events, non-compliance with the study protocol, or withdrawal of consent by the participant. The trial's design and procedures are meticulously crafted to ensure the collection of robust and reliable data, contributing to the understanding of Lu AH69593's safety and tolerability in the target population.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements is not possible with the given data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided data. As such, no further details can be included in this description.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on June 1, 2025, with an estimated completion date of November 30, 2026. The efficacy of the intervention will be evaluated using predefined endpoints, although specific primary and secondary endpoints are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The study will adhere to rigorous standards typical of Phase 3 trials, focusing on the collection of robust efficacy data to support the evaluation of the intervention's therapeutic potential.